Regresa al Registro Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorGazzah, A.
dc.contributor.authorBedard, Philippe L.
dc.contributor.authorHierro Carbó, Cinta
dc.contributor.authorKang, Yoon-Koo
dc.contributor.authorAbdul Razak, A.
dc.contributor.authorRyu, M.-H.
dc.contributor.authorTabernero Caturla, Josep
dc.date.accessioned2022-09-06T09:14:51Z
dc.date.available2022-09-06T09:14:51Z
dc.date.issued2022-04
dc.identifier.citationGazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416–25.
dc.identifier.issn0923-7534
dc.identifier.urihttp://hdl.handle.net/11351/8032
dc.descriptionConjugado anticuerpo-fármaco; Estudio de escalada de dosis; Tusamitamab ravtansina
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesAnnals of Oncology;33(4)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectCàncer - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subjectFarmacocinètica
dc.subject.meshNeoplasms
dc.subject.mesh/drug therapy
dc.subject.meshDose-Response Relationship, Drug
dc.subject.meshTreatment Outcome
dc.titleSafety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.annonc.2021.12.012
dc.subject.decsneoplasias
dc.subject.decs/farmacoterapia
dc.subject.decsrelación dosis-respuesta de medicamentos
dc.subject.decsresultado del tratamiento
dc.relation.publishversionhttps://doi.org/10.1016/j.annonc.2021.12.012
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Gazzah A] Drug Development Department, Gustave Roussy, Villejuif Cedex, Villejuif, France. [Bedard PL, Abdul Razak A] Division of Medical Oncology & Hematology, Department of Medicine, Princess Margaret Cancer Centre–University Health Network, University of Toronto, Toronto, Canada. [Hierro C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Kang YK, Ryu MH] Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Medical Oncology Department, IOB-Quiron, UVic-UCC, Barcelona, Spain
dc.identifier.pmid35026412
dc.identifier.wos000820214100008
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Regresa al Registro Simple